Clinical Trials Sponsored by SpyGlass Pharma, Inc.

Total 2368 results

Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States, Canada
Astellas Pharma Global Development, Inc.
Seagen Inc.

Approved for marketing

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma (UC)

United States
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Terminated

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Metastatic Castration Resistant Prostate Cancer

United States
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Withdrawn

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer
Tris Pharma, Inc.

Not yet recruiting

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Abuse, Drug

United States
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
ImmunoRx Pharma Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Healthy Participants

Netherlands
Telios Pharma, Inc.

Recruiting

A Study Of TL-925 For The Treatment of AC

Allergic Conjunctivitis

United States
Astellas Pharma Inc

Recruiting

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause (Starlight 2)

Hot Flashes

Japan
Telios Pharma, Inc.

Recruiting

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
Acasti Pharma Inc.

Recruiting

Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH (STRIVE-ON)

Aneurysmal Subarachnoid Hemorrhage (aSAH)

United States
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
aTyr Pharma, Inc.

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Interstitial Lung Disease

United States
Kringle Pharma, Inc.

Recruiting

Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar

Vocal Fold Scar

Japan
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Astellas Pharma Inc

Recruiting

A Study of ASP3082 in Adults With Previously Treated Solid Tumors

Solid Tumor

United States, Japan, France
CanWell Pharma Inc.

Recruiting

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Solid Tumor | Cancer Metastatic

United States
Averitas Pharma, Inc.

Recruiting

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Post Surgical Neuropathic Pain

United States, Spain, France, Netherlands, Poland, United Kingdom
Astellas Pharma Inc

Recruiting

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Rheumatoid Arthritis (RA)

Japan
Sinew Pharma Inc.

Not yet recruiting

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
Esperas Pharma Inc.

Recruiting

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Neoplasms | Soft Tissue Sarcoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Rectal Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colon Cancer | Solid Tumors | Pancreas Cancer

Canada, United States, Croatia, Poland
Astellas Pharma Inc

Active, not recruiting

Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Renal Anemia

Japan
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

China, Malaysia, Russian Federation, Singapore, Thailand
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Astellas Pharma Inc

Terminated

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Melanoma | Breast Cancer | Sentinel Lymph Node Biopsy

United States
Zurex Pharma, Inc.

Completed

Perioperative Patient Skin Antiseptic Preparation Evaluation

Surgical Site Infection

United States
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
OBI Pharma, Inc

Terminated

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumor

United States
Vincerx Pharma, Inc.

Terminated

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Relapsed Non Hodgkin Lymphoma | Richter Syndrome | MYC Amplification | MYC Overexpression | MYC Translocation

United States, Poland
Astellas Pharma Inc

Completed

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

Laparoscopic/Minimally Invasive Colorectal Surgery

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Mydriasis | Dilation

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

Dim Light Vision Disturbances

United States
Ocuphire Pharma, Inc.

Completed

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) (MIRA-3)

Mydriasis | Dilation

United States
aTyr Pharma, Inc.

Completed

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

SARS-CoV-2 (COVID-19) Severe Pneumonia

United States, Puerto Rico
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
CinCor Pharma, Inc.

Completed

A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO)

Uncontrolled Hypertension

United States
Sinew Pharma Inc.

Completed

A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study

Acetaminophen Toxicity

Taiwan
Astellas Pharma Inc

Completed

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

Acute Kidney Injury (AKI)

United States
Acasti Pharma Inc.

Active, not recruiting

Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

Postherpetic Neuralgia

Canada
InnoCare Pharma Inc.

Active, not recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
NS Pharma, Inc.

Active, not recruiting

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Duchenne Muscular Dystrophy

United States, Canada
Astellas Pharma Inc

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Secondary Hyperparathyroidism

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients

Type 2 Diabetes Mellitus

Japan
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Amarin Pharma Inc.

Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

Hypertriglyceridemia

United States
Amarin Pharma Inc.

Completed

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT)

Cardiovascular Diseases

United States, Australia, Canada, India, Netherlands, New Zealand, Poland, Romania, Russian Federation, South Africa, Ukraine
NS Pharma, Inc.

Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Irritable Bowel Syndrome With Constipation (IBS-C) | Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)

Japan

Clinical Trials Sponsored by SpyGlass Pharma, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations